Ken Fisher’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q3
Sell
-15,764
Closed -$265K 859
2018
Q2
$265K Sell
15,764
-59,075
-79% -$1.15M ﹤0.01% 724
2018
Q1
$1.71M Hold
74,839
﹤0.01% 529
2017
Q4
$1.94M Hold
74,839
﹤0.01% 520
2017
Q3
$1.1M Hold
74,839
﹤0.01% 555
2017
Q2
$1.04M Buy
74,839
+30,476
+69% +$449K ﹤0.01% 533
2017
Q1
$757K Buy
44,363
+8,200
+23% +$98.3K ﹤0.01% 526
2016
Q4
$372K Hold
36,163
﹤0.01% 597
2016
Q3
$366K Sell
36,163
-19,771
-35% -$216K ﹤0.01% 607
2016
Q2
$669K Hold
55,934
﹤0.01% 539
2016
Q1
$759K Hold
55,934
﹤0.01% 536
2015
Q4
$1.06M Hold
55,934
﹤0.01% 506
2015
Q3
$1.05M Buy
+55,934
New +$951K ﹤0.01% 488

Other funds holding CNCE

Ken Fisher's CNCE Position: Q3 2018 in Review

Ken Fisher sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2018, closing a stake of 15,764 shares — an estimated $265K sold.

Ken Fisher first reported a position in CNCE in Q3 2015 and held it in 12 quarters. The position peaked at $1.94M in Q4 2017. 111 funds tracked by Wall St. Rank hold CNCE as of Q3 2018.

  • Ken Fisher reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Ken Fisher sold 15,764 Concert Pharmaceuticals, Inc. shares in Q3 2018, an estimated $265K.
  • Ken Fisher first reported a position in Concert Pharmaceuticals, Inc. in Q3 2015 and held it in 12 quarters.
  • Ken Fisher's Concert Pharmaceuticals, Inc. position peaked at $1.94M in Q4 2017.
  • 111 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2018.

Based on Fisher Asset Management's 13F filing for Q3 2018, filed 24 Oct 2018.